Skip to main content
. 2023 Aug 4;14:143. doi: 10.1007/s12672-023-00763-7

Table 3.

Univariate and multivariate cox regression analyses for overall survival in patients with esophageal squamous cell carcinoma

Variables Univariate analysis Multivariate analysis
HR (95%CI) P value HR (95%CI) P value
Primary cohort
 Sex: male vs. female 0.66 (0.48–0.90) 0.010* 0.79 (0.57–1.09) 0.156
 Age: > 60 vs. ≤ 60 1.27 (0.99–1.63) 0.061
 Tumor location
  Lower vs. upper + middle 0.90 (0.78–1.04) 0.158
 Grade
  Poorly vs. Well + moderately 1.79 (1.39–2.30)  < 0.001* 1.68 (0.95–2.98) 0.074
 T stage
  T2–4a vs. T1 3.01 (2.12–4.27)  < 0.001* 2.27 (1.58–3.28)  < 0.001*
 N stage
  N1–3 vs. N0 2.80 (2.17–3.61)  < 0.001* 2.02 (1.54–2.65)  < 0.001*
 TNM stage
  II–IVa vs. I 3.86 (2.57–5.80)  < 0.001* 3.57 (2.37–5.37)  < 0.001*
 Fibrinogen: ≥ 3.5 vs. < 3.5 1.46 (1.14–1.88) 0.003* 1.35 (1.05–1.74) 0.019*
 NLR: ≥ 1.95 vs. < 1.95 1.47 (1.13–1.89) 0.003* 1.33 (1.03–1.73) 0.031*
 PLR: ≥ 130 vs. < 130 1.32 (1.03–1.69) 0.031* 1.19 (0.93–1.53) 0.164
 MLR: ≥ 0.25 vs. < 0.25 1.34 (1.04–1.73) 0.025* 1.17 (0.90–1.51) 0.242
 F-NLR
  1–2 vs. 0 1.62 (1.20–2.18) 0.002* 1.39 (1.03–1.88) 0.030*
Validation cohort
 Sex: male vs. female 0.66 (0.37–1.15) 0.139
 Age: > 60 vs. ≤ 60 0.93 (0.60–1.44) 0.742
 Tumor location
  Lower vs. upper + middle 1.02 (0.80–1.30) 0.877
 Grade
  Poorly vs. well + moderately 2.33 (1.48–3.68)  < 0.001* 1.87 (1.18–2.97) 0.008*
 T stage
  T2–4a vs. T1 2.79 (1.39–5.58)  < 0.001* 2.16 (1.07–4.37) 0.032*
 N stage
  N1–3 vs. N0 2.45 (1.57–3.83)  < 0.001* 1.84 (1.16–2.91) 0.010*
 TNM stage
  II–IVa vs. I 3.24 (1.41–7.44) 0.006* 2.62 (1.13–6.10) 0.026*
 Fibrinogen: ≥ 3.5 vs. < 3.5 1.80 (1.15–2.81) 0.010* 1.60 (1.02–2.51) 0.039*
 NLR: ≥ 1.95 vs. < 1.95 1.96 (1.26–3.04) 0.003* 1.81 (1.14–2.87) 0.012*
 PLR: ≥ 130 vs. < 130 1.64 (1.05–2.57) 0.031* 1.55 (0.98–2.44) 0.059
 MLR: ≥ 0.25 vs. < 0.25 1.72 (1.08–2.74) 0.022* 1.50 (0.94–2.42) 0.092
 F-NLR
  1–2 vs. 0 1.96 (1.10–3.48) 0.023* 1.84 (1.03–3.27) 0.039*

F-NLR: Fibrinogen-neutrophil lymphocyte ratio; NLR: neutrophil lymphocyte ratio; PLR: platelet lymphocyte ratio; MLR: monocyte to lymphocyte ratio